BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies

Date 03 March 2015
Event 13th International Congress on Targeted Anticancer Therapies
Session Epigenetics and chaperones
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Haematologic Malignancies
Presenter Patrice Herait